BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 94.4%

Neg 94.4% Neu 0% Pos 0%

BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $18.